Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

VEGF-Trap: A VEGF blocker with potent antitumor effects

Open access

Abstract

Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. Initial attempts to block VEGF by using a humanized monoclonal antibody are beginning to show promise in human cancer patients, underscoring the importance of optimizing VEGF blockade. Previous studies have found that one of the most effective ways to block the VEGF-signaling pathway is to prevent VEGF from binding to its normal receptors by administering decoy-soluble receptors. The highest-affinity VEGF blocker described to date is a soluble decoy receptor created by fusing the first three Ig domains of VEGF receptor 1 to an Ig constant region; however, this fusion protein has very poor in vivo pharmacokinetic properties. By determining the requirements to maintain high affinity while extending in vivo half life, we were able to engineer a very potent high-affinity VEGF blocker that has markedly enhanced pharmacokinetic properties. This VEGF-Trap effectively suppresses tumor growth and vascularization in vivo , resulting in stunted and almost completely avascular tumors. VEGF-Trap-mediated blockade may be superior to that achieved by other agents, such as monoclonal antibodies targeted against the VEGF receptor.

Overview

Integrity signals

Registry

Crossref · 10.1073/pnas.172398299

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Research works printed but not linked: 11

  1. Pezzella F., Pastorino, U., Tagliabue, E., Andreola, S., Sozzi, G., Gasparini, G., Menard, S., Gatter, K. C., Harris, A. L., Fox, S., et al. (1997) Am. J. Pathol.151,1417-1423.9358768
  2. Eriksson U. & Alitalo, K. (1999) Curr. Top. Microbiol. Immunol.237,41-57.9893345
  3. Ferrara N. (1999) Curr. Top. Microbiol. Immunol.237,1-30.9893343
  4. Prewett M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P. & Hicklin, D. J. (1999) Cancer Res.59,5209-5218.10537299
  5. Millauer B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A. & Strawn, L. M. (1996) Cancer Res.56,1615-1620.8603410
  6. Fong T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) Cancer Res.59,99-106.9892193
  7. Drevs J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Muller, M., Wood, J., Martiny-Baron, G., Unger, C. & Marme, D. (2000) Cancer Res.60,4819-4824.10987292
  8. Wedge S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Curwen, J. O., Hennequin, L. F., Thomas, A. P., Stokes, E. S., Curry, B., Richmond, G. H., et al. (2000) Cancer Res.60,970-975.10706112
  9. Gerber H. P., Kowalski, J., Sherman, D., Eberhard, D. A. & Ferrara, N. (2000) Cancer Res.60,6253-6258.11103779
  10. Lin Y. S., Nguyen, C., Mendoza, J. L., Escandon, E., Fei, D., Meng, Y. G. & Modi, N. B. (1999) J. Pharmacol. Exp. Ther.288,371-378.9862791
  11. Qaum T., Xu, Q., Joussen, A. M., Clemens, M. W., Qin, W., Miyamoto, K., Hassessian, H., Wiegand, S. J., Rudge, J., Yancopoulos, G. D. & Adamis, A. P. (2001) Invest. Ophthalmol. Visual Sci.42,2408-2413.11527957

Cited by

See all 1,691

Metadata

Authors
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., & Rudge, J. S.
Affiliations
  • Regeneron (United States) (US)
  • Regeneron Pharmaceuticals, Incorporated, 777 Old Saw Mill River Road, Tarrytown, NY 10591
Venue
Proceedings of the National Academy of Sciences
Published
2002-08-12
Volume
99
Issue
17
Pages
11393-11398
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1980725734
Cited by
1,691
References
39
Citations by year
2026: 19 · 2025: 31 · 2024: 40 · 2023: 50 · 2022: 51 · 2021: 80 · 2020: 60 · 2019: 60 · 2018: 65 · 2017: 81 · 2016: 111 · 2015: 101 · 2014: 111 · 2013: 113 · 2012: 118
FWCI
15.34
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords
VEGF trap, vascular endothelial growth factor, VEGF receptor 1, VEGF inhibition, tumor angiogenesis, anticancer activity, pharmacokinetics, tumor vascularization, humanized monoclonal antibody, protein engineering
MeSH terms
Animals, Antineoplastic Agents, Bone Neoplasms, Cell Division, Endothelium, Vascular, Extracellular Matrix, Humans, Immunoglobulin G, Immunoglobulin Constant Regions, Lymphokines, Melanoma, Experimental, Mice, Inbred BALB C, Phosphorylation, Proto-Oncogene Proteins, Rhabdomyosarcoma, Umbilical Veins, Drug Design, Protein Engineering, Endothelial Growth Factors, 3T3 Cells, Receptor Protein-Tyrosine Kinases, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: VEGF-Trap: A VEGF blocker with potent antitumor effects. https://app.cochat.ai/papers/10.1073/pnas.172398299
The paper
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., Ioffe, E., Huang, T., Radziejewski, C., Bailey, K., Fandl, J. P., Daly, T., Wiegand, S. J., Yancopoulos, G. D., & Rudge, J. S. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.172398299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.